These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 15690331

  • 1. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
    Dejmek A, Hjerpe A.
    Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331
    [Abstract] [Full Text] [Related]

  • 2. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE, Novelli L, Boddi V, Paglierani M, Dini S.
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [Abstract] [Full Text] [Related]

  • 3. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT, Gentile P, Tarectecan A, Fuchs A.
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [Abstract] [Full Text] [Related]

  • 4. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
    Kayser K, Böhm G, Blum S, Beyer M, Zink S, André S, Gabius HJ.
    J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
    Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K.
    Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
    [Abstract] [Full Text] [Related]

  • 6. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY, Li GD, Liu WP, Xie B, Jiang YH.
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [Abstract] [Full Text] [Related]

  • 7. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K.
    Pneumonol Alergol Pol; 2007 Dec; 75(1):57-69. PubMed ID: 17541913
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of membranous staining of mesothelioma.
    King JA, Tucker JA.
    Cell Vis; 1998 Dec; 5(1):24-7. PubMed ID: 9660721
    [Abstract] [Full Text] [Related]

  • 9. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM, Stern R, Michael CW.
    Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR, Zhai J.
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [Abstract] [Full Text] [Related]

  • 12. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
    Dejmek A, Hjerpe A.
    Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
    [Abstract] [Full Text] [Related]

  • 13. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
    Chenard-Neu MP, Kabou A, Mechine A, Brolly F, Orion B, Bellocq JP.
    Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912
    [Abstract] [Full Text] [Related]

  • 14. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M, Hoogsteden HC, Van der Kwast TH.
    J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
    [Abstract] [Full Text] [Related]

  • 15. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
    Galateau-Salle F.
    Arch Anat Cytol Pathol; 1993 Oct; 41(5-6):212-22. PubMed ID: 8135582
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
    Chenard-Neu MP, Bellocq JP, Maier A, Batzenschlager A.
    Ann Pathol; 1990 Oct; 10(1):20-7. PubMed ID: 2328062
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
    Mezger J, Lamerz R, Permanetter W.
    J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.